These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5784376)

  • 21. [Further clinical experiences with ornithine aspartate in liver diseases].
    Wotzka R; Weber D
    Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
    [No Abstract]   [Full Text] [Related]  

  • 22. [Silymarin and various problems of current therapy of chronic liver diseases].
    Fassati P; Fassati M
    Cas Lek Cesk; 1973; 112(28):865-9. PubMed ID: 4720441
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical and biological effectiveness of citiolone and importance of its contribution in hepatic therapeutics].
    Duché G
    Therapeutique; 1970 Dec; 46(10):1037-41. PubMed ID: 5511931
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hepatoprotective drugs. Clinical results of the use of a sulfhydryl-methylating preparation].
    Rapino P; Marulli R; Rapex G; Della Lunga S; Sabatino P
    Minerva Med; 1982 Oct; 73(40):2853-60. PubMed ID: 7133498
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects of administration of arginine thiazolidinecarboxylate in liver pathology of various origins. Results of a multicenter study].
    Gasbarrini G; Bernardi M
    Minerva Dietol Gastroenterol; 1982; 28(2):143-52. PubMed ID: 7099448
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antioxidant therapy in chronic liver diseases].
    Lengyel G; Tulassay Z
    Orv Hetil; 2006 Jun; 147(24):1113-8. PubMed ID: 16865855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience in the treatment of chronic hepatopathies with silymarin].
    Poser G
    Arzneimittelforschung; 1971 Aug; 21(8):1209-12. PubMed ID: 5110021
    [No Abstract]   [Full Text] [Related]  

  • 28. [Our experience with long-term therapy of chronic liver diseases using Superanabolon Spofa].
    Svacinka P; Horký J; Blahníková L
    Vnitr Lek; 1970 Dec; 16(12):1181-7. PubMed ID: 5491517
    [No Abstract]   [Full Text] [Related]  

  • 29. [For which liver diseases is immunosuppressive therapy indicated?].
    Bannaski H
    Med Klin Prax; 1982 Aug; 77(16-17):66-71, 74. PubMed ID: 7132889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ambulatory treatment of hepatic damage: comparison of 2 therapeutic modalities].
    Ravetta A
    Clin Ter; 1981 Oct; 99(2):149-53. PubMed ID: 7318368
    [No Abstract]   [Full Text] [Related]  

  • 31. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of ornithine carbamoyltransferase in the treatment of liver diseases].
    Caruso N; De Jacobis M; Roccato M; Sequino A; Sgoifo B; Tinello M
    Clin Ter; 1984 Jul; 110(1):37-44. PubMed ID: 6237844
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparative clinical trial of karsil and legalon in patients with chronic liver lesions. III. Comparison of the effect of karsil and legalon on a 3-point system].
    Krŭstev Z; Ognianov M; Lukanov L; Ivanchev T; Mateva L
    Vutr Boles; 1984; 23(4):37-9. PubMed ID: 6390971
    [No Abstract]   [Full Text] [Related]  

  • 34. [The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis].
    Váli L; Blázovics A; Fehér J
    Orv Hetil; 2005 Nov; 146(47):2409-14. PubMed ID: 16398154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the therapeutic effects of silymarin].
    Margaroli P; Rossi M; Arcabasso GD; Cosini I; Malacrida C
    Clin Ter; 1980 Dec; 95(6):663-72. PubMed ID: 7214856
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of asparagine on hepatic physiopathological syndromes].
    Fodor O; Cotul S; Barbarino F; Grigoras D; Nicoară A; Suciu A
    Stud Cercet Med Interna; 1968; 9(5):405-14. PubMed ID: 5716055
    [No Abstract]   [Full Text] [Related]  

  • 37. [Milk thistle (Silybum marianum) derivatives in the therapy of chronic hepatopathies].
    De Martiis M; Fontana M; Assogna G; D'Ottavi R; D'Ottavi O
    Clin Ter; 1980 Aug; 94(3):283-315. PubMed ID: 7004762
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of Catergen [(+)cyanidanol-3] on some haemostatic parameters in chronic liver diseases.
    Pfliegler G; Boda Z; Dalmi L; Weisz G; Misz M; Beck P
    Ther Hung; 1984; 32(1):19-25. PubMed ID: 6571189
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinico-morphological dynamics of chronic diffuse liver diseases].
    Loginov AS; Blok IuE; Shepeleva SD; Tkachev VD
    Ter Arkh; 1981; 53(11):50-9. PubMed ID: 7339906
    [No Abstract]   [Full Text] [Related]  

  • 40. [Sylimarine in the treatment of chronic hepatitis].
    Sawaryn T; Szymoński K; Machalska M
    Przegl Epidemiol; 1977; 31(4):445-50. PubMed ID: 607279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.